Last reviewed · How we verify
Long acting octreotide 10mg
Long acting octreotide 10mg is a Small molecule drug developed by Mayo Clinic. It is currently in Phase 1 development. Also known as: Long-acting octreotide.
Long-acting octreotide 10mg, developed by Mayo Clinic, is a somatostatin analog used primarily for off-label treatments. It has shown promise in reducing portal pressure in cirrhotic patients but lacks FDA approval. Limited trials and no commercial data are available.
At a glance
| Generic name | Long acting octreotide 10mg |
|---|---|
| Also known as | Long-acting octreotide |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long acting octreotide 10mg CI brief — competitive landscape report
- Long acting octreotide 10mg updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about Long acting octreotide 10mg
What is Long acting octreotide 10mg?
Long acting octreotide 10mg is a Small molecule drug developed by Mayo Clinic.
Who makes Long acting octreotide 10mg?
Long acting octreotide 10mg is developed by Mayo Clinic (see full Mayo Clinic pipeline at /company/mayo-clinic).
Is Long acting octreotide 10mg also known as anything else?
Long acting octreotide 10mg is also known as Long-acting octreotide.
What development phase is Long acting octreotide 10mg in?
Long acting octreotide 10mg is in Phase 1.
Related
- Manufacturer: Mayo Clinic — full pipeline
- Also known as: Long-acting octreotide
- Compare: Long acting octreotide 10mg vs similar drugs
- Pricing: Long acting octreotide 10mg cost, discount & access